References

Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata

10.1172/jci.insight.89776 · 2016 · External reference

Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers

10.1111/exd.13060 · 2016 · External reference

Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata

10.1172/jci.insight.89790 · 2016 · External reference

10.1016/j.ebiom.2016.03.036

10.1016/j.ebiom.2016.03.036 · External reference

Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation

10.1016/s0190-9622(99)70195-7 · 1999 · External reference

10.1093/imammb/dqx009

10.1093/imammb/dqx009 · External reference

Toward predicting the spatio-temporal dynamics of alopecia areata lesions using partial differential equation analysis

10.1007/s11538-020-00707-0 · 2020 · External reference

JAK inhibitors and alopecia areata

10.1016/s0140-6736(18)32987-8 · 2019 · External reference

Master regulators of infiltrate recruitment in autoimmune disease identified through network-based molecular deconvolution

10.1016/j.cels.2015.11.001 · 2015 · External reference

ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context

10.1186/1471-2105-7-s1-s7 · 2006 · External reference

Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata

2021 · External reference

10.1016/j.ccr.2006.02.019

10.1016/j.ccr.2006.02.019 · External reference

10.1038/msb.2010.31

10.1038/msb.2010.31 · External reference

A systems biology approach to prediction of oncogenes and molecular perturbation targets in B-cell lymphomas

10.1038/msb.2008.2 · 2008 · External reference

10.1016/j.cell.2015.05.056

10.1016/j.cell.2015.05.056 · External reference

10.1007/s11010-011-0956-5

10.1007/s11010-011-0956-5 · External reference